When hormonal treatment is not an option
An integrated analysis of safety data from seven Phase 2/3 double-blind, placebo-controlled trials has been conducted for ospemifene (Senshio ®). Adverse drug reactions are well characterized, benign and not unexpected from a SERM used for the treatment of VVA (i.e. hot flushes, leg cramps). There is no evidence to date that ospemifene leads to an increase in vaginal bleeding, endometrial hyperplasia or cancer; VTE, stroke or other cardi ovascular events; or any other adverse event of special interest.
Source: Maturitas - Category: Primary Care Authors: Felix Lugo Source Type: research
More News: Bleeding | Cancer | Cancer & Oncology | Drugs & Pharmacology | Endometrial Cancer | Hormones | Primary Care | Stroke